Selected research
Industry Research
Candidiasis Drug Industry Research Report 2026
Market perspective
The global Candidiasis Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Candidiasis Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Candidiasis Drug market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Candidiasis Drug market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Candidiasis Drug include Bristol-Myers Squibb, Cisen Pharmaceutical, Effik, Kingyork Group, Perrigo, Bayer, Pfizer, J & J and Sanofi and among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Candidiasis Drug market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Candidiasis Drug.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Candidiasis Drug Market by Company
Bristol-Myers Squibb
Cisen Pharmaceutical
Effik
Kingyork Group
Perrigo
Bayer
Pfizer
J & J
Sanofi
Teva
Candidiasis Drug Segment by Type
Oral
External Use
Other
Candidiasis Drug Segment by Application
Hospital
Retail Pharmacy
Other
Candidiasis Drug Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Candidiasis Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Candidiasis Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Candidiasis Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Candidiasis Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Oral
- External Use
- Other
Applications
- Hospital
- Retail Pharmacy
- Other
Companies covered
- Bristol-Myers Squibb
- Cisen Pharmaceutical
- Effik
- Kingyork Group
- Perrigo
- Bayer
- Pfizer
- J & J
- Sanofi
- Teva
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Candidiasis Drug by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Oral
- 2.2.3 External Use
- 2.2.4 Other
- 2.3 Candidiasis Drug by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospital
- 2.3.3 Retail Pharmacy
- 2.3.4 Other
- 2.4 Assumptions and Limitations
3 Candidiasis Drug Breakdown Data by Type
- 3.1 Global Candidiasis Drug Historic Market Size by Type (2021-2026)
- 3.2 Global Candidiasis Drug Forecasted Market Size by Type (2027-2032)
4 Candidiasis Drug Breakdown Data by Application
- 4.1 Global Candidiasis Drug Historic Market Size by Application (2021-2026)
- 4.2 Global Candidiasis Drug Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Candidiasis Drug Market Perspective (2021-2032)
- 5.2 Global Candidiasis Drug Growth Trends by Region
- 5.2.1 Global Candidiasis Drug Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Candidiasis Drug Historic Market Size by Region (2021-2026)
- 5.2.3 Candidiasis Drug Forecasted Market Size by Region (2027-2032)
- 5.3 Candidiasis Drug Market Dynamics
- 5.3.1 Candidiasis Drug Industry Trends
- 5.3.2 Candidiasis Drug Market Drivers
- 5.3.3 Candidiasis Drug Market Challenges
- 5.3.4 Candidiasis Drug Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Candidiasis Drug Players by Revenue
- 6.1.1 Global Top Candidiasis Drug Players by Revenue (2021-2026)
- 6.1.2 Global Candidiasis Drug Revenue Market Share by Players (2021-2026)
- 6.2 Global Candidiasis Drug Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Candidiasis Drug Head Office and Area Served
- 6.4 Global Candidiasis Drug Players, Product Type & Application
- 6.5 Global Candidiasis Drug Manufacturers Established Date
- 6.6 Global Candidiasis Drug Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Candidiasis Drug Market Size (2021-2032)
- 7.2 North America Candidiasis Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Candidiasis Drug Market Size by Country (2021-2026)
- 7.4 North America Candidiasis Drug Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Candidiasis Drug Market Size (2021-2032)
- 8.2 Europe Candidiasis Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Candidiasis Drug Market Size by Country (2021-2026)
- 8.4 Europe Candidiasis Drug Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Candidiasis Drug Market Size (2021-2032)
- 9.2 Asia-Pacific Candidiasis Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Candidiasis Drug Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Candidiasis Drug Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Candidiasis Drug Market Size (2021-2032)
- 10.2 South America Candidiasis Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Candidiasis Drug Market Size by Country (2021-2026)
- 10.4 South America Candidiasis Drug Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Candidiasis Drug Market Size (2021-2032)
- 11.2 Middle East & Africa Candidiasis Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Candidiasis Drug Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Candidiasis Drug Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Bristol-Myers Squibb
- 12.1.1 Bristol-Myers Squibb Company Information
- 12.1.2 Bristol-Myers Squibb Business Overview
- 12.1.3 Bristol-Myers Squibb Revenue in Candidiasis Drug Business (2021-2026)
- 12.1.4 Bristol-Myers Squibb Candidiasis Drug Product Portfolio
- 12.1.5 Bristol-Myers Squibb Recent Developments
- 12.2 Cisen Pharmaceutical
- 12.2.1 Cisen Pharmaceutical Company Information
- 12.2.2 Cisen Pharmaceutical Business Overview
- 12.2.3 Cisen Pharmaceutical Revenue in Candidiasis Drug Business (2021-2026)
- 12.2.4 Cisen Pharmaceutical Candidiasis Drug Product Portfolio
- 12.2.5 Cisen Pharmaceutical Recent Developments
- 12.3 Effik
- 12.3.1 Effik Company Information
- 12.3.2 Effik Business Overview
- 12.3.3 Effik Revenue in Candidiasis Drug Business (2021-2026)
- 12.3.4 Effik Candidiasis Drug Product Portfolio
- 12.3.5 Effik Recent Developments
- 12.4 Kingyork Group
- 12.4.1 Kingyork Group Company Information
- 12.4.2 Kingyork Group Business Overview
- 12.4.3 Kingyork Group Revenue in Candidiasis Drug Business (2021-2026)
- 12.4.4 Kingyork Group Candidiasis Drug Product Portfolio
- 12.4.5 Kingyork Group Recent Developments
- 12.5 Perrigo
- 12.5.1 Perrigo Company Information
- 12.5.2 Perrigo Business Overview
- 12.5.3 Perrigo Revenue in Candidiasis Drug Business (2021-2026)
- 12.5.4 Perrigo Candidiasis Drug Product Portfolio
- 12.5.5 Perrigo Recent Developments
- 12.6 Bayer
- 12.6.1 Bayer Company Information
- 12.6.2 Bayer Business Overview
- 12.6.3 Bayer Revenue in Candidiasis Drug Business (2021-2026)
- 12.6.4 Bayer Candidiasis Drug Product Portfolio
- 12.6.5 Bayer Recent Developments
- 12.7 Pfizer
- 12.7.1 Pfizer Company Information
- 12.7.2 Pfizer Business Overview
- 12.7.3 Pfizer Revenue in Candidiasis Drug Business (2021-2026)
- 12.7.4 Pfizer Candidiasis Drug Product Portfolio
- 12.7.5 Pfizer Recent Developments
- 12.8 J & J
- 12.8.1 J & J Company Information
- 12.8.2 J & J Business Overview
- 12.8.3 J & J Revenue in Candidiasis Drug Business (2021-2026)
- 12.8.4 J & J Candidiasis Drug Product Portfolio
- 12.8.5 J & J Recent Developments
- 12.9 Sanofi
- 12.9.1 Sanofi Company Information
- 12.9.2 Sanofi Business Overview
- 12.9.3 Sanofi Revenue in Candidiasis Drug Business (2021-2026)
- 12.9.4 Sanofi Candidiasis Drug Product Portfolio
- 12.9.5 Sanofi Recent Developments
- 12.10 Teva
- 12.10.1 Teva Company Information
- 12.10.2 Teva Business Overview
- 12.10.3 Teva Revenue in Candidiasis Drug Business (2021-2026)
- 12.10.4 Teva Candidiasis Drug Product Portfolio
- 12.10.5 Teva Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst